3SOF

"AVII" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.     
All history on a stock pick in 1 thread is awesome.     

Thank You....and good luck with all your trades....make some $$$   

In play....premarket news. A good size contract  Department of Defense
The contract will fund AVII's development of antisense therapeutics to treat the effects of Ebola, Marburg and Junin hemorrhagic viruses, which are seen as biological warfare and bio-terrorism agents.

Bounced back above the 50-day MA on the news.

52wk Range: 2.55 - 9.20
Volume: 2,032,222
Avg Vol (3m): 675,223

Technicals
Gap Up
Percentage Gainer

Last Price Quote is:
6.61%above 13-day MA
4.48%above 50-day MA
RS Rating: 15 

Fundamentals
Key Data:
Market Cap (M): $189.60 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/07/2007
Last Analyst Rating: Mkt Outperform

Below are the 6 month and 1 year charts.

Quote from: setravis on December 04, 2006, 05:27:40 PM
In play....premarket news. A good size contract  Department of Defense
The contract will fund AVII's development of antisense therapeutics to treat the effects of Ebola, Marburg and Junin hemorrhagic viruses, which are seen as biological warfare and bio-terrorism agents.

Bounced back above the 50-day MA on the news.

Setravis,

Lousy response to that $28 million contract, huh?

"Gap To Crap," up to 4.17, then down ever since.  Go figger.

Quote from: Melf Elf on November 10, 2006, 04:01:20 AM
Sold remaining ½ position in AVII yesterday morning at 3.83.  Gain: 3.2%

Gain on the trade: 7.1%

I wanted to buy back that position at the bottom of the channel.  Seems like it's overdue for a rally, but with two closes below the channel, I have to pass. 

AVII showing signs of life... could be good for a little relief rally if it breaks 2.70. 

Maxim Group initiates AVII with a buy and $5 target.  Also the CEO has just resigned, so maybe the reshuffle will give an indication of a turnaround in their fortunes

Sector Snap: Avian Flu Vaccines.......
Influenza Vaccine Makers Move After Positive Preclinical Data From Novavax

Positive preclinical results from a bird flu vaccine helped boost several companies working to develop similar technology as fears over a possible pandemic linger.

Rockville, Md.-based Novavax Inc. said Monday its virus-like particle vaccine, which mimics a virus, was effective in evoking an immune response in ferrets and protecting against the H9N2 strain. The vaccine has previously been tested in mice with the H9N2 strain of avian influenza, or bird flu.

Bird flu has now traveled through large swaths of the globe and has been reported in Asia, Africa and Europe, often resulting in large bird culls. Several other companies developing flu vaccines and listed on the Nasdaq gained during the trading session.

AVI Biopharma Inc. is working on developing Neugene to target various strains of the disease, including those that primarily affect humans, such as H1N1, H2N2 and H3N2, as well as those that have spread to bird flocks and have scientists worried they could mutate and cause a pandemic.

Support @ $2.78...2.39...2.17
Resistance @ $3.16...3.58...3.69

52wk Range: 2.33 - 7.33
Volume: 1,717,012
Avg Vol (3m): 540,705

Technicals
Percentage Gainer

Last Price Quote is:
15.59%above 13-day MA
13.41%above 50-day MA
RS Rating: 28 

Fundamentals
Key Data:
Market Cap (M): $189.60 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/11/2007
Last Analyst Rating: Buy

Amazing pipeline, great technology.
Market cap is absurd for a company with this kind of technology and pipeline.
They're looking for a new CEO.
This is not an investment for the impatient.
Looks like the MACD is going to get the bounce off the center line.

52wk Range: 2.33 - 5.07
Volume: 647,483
Avg Vol (3m): 565,543

Technicals
Close Above the 50-day MA
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
3.09%above 13-day MA
3.05%above 50-day MA
RS Rating: 29 

Fundamentals
Key Data:
Market Cap (M): $154.52 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2007
Last Analyst Rating: Buy

Uptrend intact.......
MACD staying above center, very good signal. Stochastic way oversold.
Closed above the 13 and 50-day MA's.
Looks like we got an Ascending Triangle (continuation) Pattern


52wk Range: 2.33 - 4.89
Volume: 698,434
Avg Vol (3m): 509,961

Technicals
Stochastic - Bullish
Percentage Gainer

Last Price Quote is:
5.53%above 13-day MA
6.60%above 50-day MA
RS Rating: 89 

Fundamentals
Key Data:
Market Cap (M): $151.77 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2007
Last Analyst Rating: Buy

The effect of the coil spring...the quiet before the storm !
Symmetrical Triangle (continuation) Pattern.

52wk Range: 2.33 - 4.89
Volume: 1,104,854
Avg Vol (3m): 577,314

Technicals
Percentage Gainer

Last Price Quote is:
5.98%above 13-day MA
5.53%above 50-day MA
RS Rating: 71 

Fundamentals
Key Data:
Market Cap (M): $153.38 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/07/2007
Last Analyst Rating: Buy

just fyi:
AVII: J.M. Dutton Cuts to Speculative Buy from Strong Speculative Buy; Sets Tgt @ $6; Analyst Notes
Monday , July 02, 2007 12:58ET

Issuer: AVI BioPharma Inc (NasdaqNM: AVII)

Analyst Firm:  J.M. Dutton & Associates, LLC

Ratings Action: DOWNGRADE

Current Rating: Speculative Buy (from Strong Speculative Buy)

Target Price Action: INITIATE
Target Price: $6.00

Analyst Comments: According to the firm, AVII stock has been relatively flat thus far in 2007 and its near term price movement remains difficult to predict - as is the case for most development-stage healthcare companies. Nevertheless, they continue to be impressed with the broad applicability and promise of AVII's differentiated technology in the treatment of many diseases, and judge that the Company has many programs that, individually, could eventually generate significant earnings. However, in part because the firm has lowered their near term financial expectations and do not yet have estimates for 2008, they have extended their price target of $6.00 per share by a year, to the end of 2008.

&

AVII: Volume Spike; 40% > 20-adsv, Stock +8.04%
Monday , July 09, 2007 14:10ET

This is the 1st VOLUME alert for AVII in the past 7 calendar days.

Trading for AVI BioPharma Inc (NASDAQ NM: AVII) has been heavier than usual in today's session. By 14:10 ET, the stock had already traded 880,600 shares via 1,589 trades. The cumulative volume is 40.07% above its 20-day average of 628,675. Normally the stock experiences around 1,053 individual trades per session.

So far, today's volume surge has caused a net rise in AVII's stock price. At the time of this alert, the stock was trading at $3.090, up $0.230 (+8.04%).

One year ago, the Company's shares closed at $3.510. The price has declined more than 11 percent since then.

Over the last 10 trading session AVII has traded in a range between $2.750 and $3.010 and is currently trading 36.81% below its 52-week high of $4.890 set on October 23,2006 and 32.61% above its 52-week low of $2.330 from March 21,2007.

In the previous 3 sessions, AVII trading has displayed a mixed trend. Closing results have been as follows:

July 06, 2007 --- closed at $2.860 up $0.050 (+1.78%) on 698,800 shares
July 05, 2007 --- closed at $2.810 down $0.060 (-2.09%) on 447,300 shares
July 03, 2007 --- closed at $2.870 up $0.070 (+2.50%) on 245,700 shares

The Company last released news on July 02, 2007:

"Dutton Associates Announces Investment Opinion: AVI BioPharma Speculative Buy Rating in Update Coverage by Dutton Associates"

Press Release Source: AVI BioPharma, Inc.


AVI BioPharma Receives Major Research and Development Grant From Charley's Fund for Duchenne Muscular Dystrophy
Monday October 15, 9:00 am ET 
$2.45 Million Will Fund Research and Product Development Program


PORTLAND, Ore., & SOUTH EGREMONT, Mass.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII - News), and Charley's Fund, Inc., today announced that AVI has been awarded a $2.45 million research grant from Charley's Fund, a nonprofit organization that funds drug development and discovery initiatives specific to Duchenne muscular dystrophy (DMD). This award, the largest grant ever made by Charley's Fund and the largest received by AVI from a nonprofit foundation, will support a new product development program using proprietary exon skipping technologies developed by AVI and its partner, Ercole Biotech, Inc., to overcome the effects of certain genetic errors in the dystrophin gene. The award will allow AVI to accelerate its development of new therapeutics for DMD, a top priority for the company.


"The technologies developed by AVI and its collaborators have incredible promise in addressing the fundamental cause of DMD: the lack of functioning dystrophin protein," said Benjamin Seckler, M.D., president of Charley's Fund. "Exon skipping offers the greatest hope for thousands of boys whose futures are in question because of this aggressive disease. We are optimistic that this research collaboration will lead to a human clinical trial in the United States to treat this generation of children with DMD."

DMD is a devastating and incurable muscle-wasting disease associated with specific in-born errors in the gene that expresses dystrophin. Dystrophin is a protein that plays an important structural role in muscle fibers. When dystrophin is missing or nonfunctional due to a mutation in the dystrophin gene, as it is in DMD, the result is membrane leakage and fiber damage, ultimately leading to degeneration and death of the muscle fiber. In two-thirds of DMD cases, the genetic mistake is hereditary, but one-third of cases arise spontaneously.

"The directors of Charley's Fund take their mission to find a cure for DMD very seriously. We at AVI are also passionate about this goal and are extremely honored by their recognition of AVI's progress with exon skipping technology," said K. Michael Forrest, interim chief executive officer of AVI. "With excellent preclinical data in hand, we believe our ESPRIT exon skipping technology holds great promise for developing products to treat this devastating disease. We look forward to getting started on the research and product development program immediately."

The focus of the funded program will be to select and develop a lead molecule, based on AVI's proprietary NEUGENE® chemistry, that is designed to skip dystrophin exon 50 to restore the proper RNA reading frame and production of functional dystrophin in patients with a particular type of mutation. This therapeutic approach is similar to that of AVI-4658, in development to potentially treat DMD patients with mutations that could benefit from skipping exon 51 of the dystrophin gene.

Funding under the Charley's Fund grant is anticipated over the next several quarters. The exon 50 candidate will be developed by AVI and its cross-licensing and collaboration partner, Ercole Biotech, under an agreement signed by the two companies in May 2007. The program brings together experts on exon skipping from around the world in a significant collaboration that may benefit the DMD population worldwide.

The technologies developed by Ercole and AVI allow manipulation of the RNA splicing process and the production by cells of clinically desirable variants of relevant proteins. AVI refers to its therapeutic approach as ESPRIT (Exon Skipping Pre-RNA Interference Technology). Ercole uses the term Splice Switching Oligonucleotide (SSO) in referring to its drug discovery platform to redirect mRNA splicing. AVI believes that its NEUGENE chemistry is particularly well-suited to modify RNA splicing.

About Duchenne Muscular Dystrophy

DMD is the most common fatal genetic disorder to affect children around the world. Children with DMD cannot produce dystrophin, a protein necessary for muscle strength and function. As a result, every skeletal muscle in the body deteriorates. There is no cure or effective treatment for DMD. Approximately one in 3,500 boys is born with DMD, and an estimated 15,000 to 20,000 children are afflicted in the United States alone.

About Charley's Fund

Charley's Fund is a not-for-profit foundation that finances therapeutics development for Duchenne muscular dystrophy. The foundation's mission is to expedite a treatment or cure in time to help this generation of children who suffer from DMD. Charley's Fund targets translational research--research that moves science from the lab into human clinical trials. The 501 (c)(3) public charity was co-founded in 2004 by Benjamin Seckler, M.D. and Tracy Kramer Seckler, whose 6-year-old son Charley has Duchenne muscular dystrophy. To learn more about Charley's Fund, visit www.charleysfund.org.

About Ercole Biotech

Ercole Biotech creates and develops oligonucleotide-based RNA therapeutics that direct alternative splicing of messenger RNA, an essential cellular mechanism responsible for control of gene expression. Splice switching oligonucleotide drugs promise to become a major new class of pharmaceuticals, capable of inducing production of therapeutic proteins by the patient's own body, as well as silencing the expression of undesired proteins. Ercole's SSO technology is based on pioneering discoveries and inventions related to oligonucleotide-induced modulation of alternative splicing and RNA repair originating from the laboratory of Professor Ryszard Kole, Ph.D., at the University of North Carolina School of Medicine. See www.ercolebiotech.com for more information about the company and its drug discovery platform.

About AVI BioPharma

AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense drugs and ESPRIT exon skipping technology. AVI's ESPRIT technology is initially being applied to potential treatments for Duchenne muscular dystrophy. AVI's lead NEUGENE compound is designed to target cell proliferation disorders, including cardiovascular restenosis. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single-stranded RNA viruses, including dengue virus, Ebola virus and H5N1 avian influenza virus. More information about AVI is available on the company's Web site at http://www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.


Contact:
AVI Contact:
AVI BioPharma, Inc.
Michael Hubbard, [email protected]
503-227-0554
or
AVI Investor Contacts:
Lippert/Heilshorn & Associates Inc.
Brandi Floberg, [email protected]
Jody Cain, [email protected]
310-691-7100
or
AVI Press Contact:
Waggener Edstrom Worldwide Healthcare
Jenny Moede, [email protected]
503-443-7000
or
Charley's Fund Contact:
Tracy Seckler, [email protected]
413-528-5744
http://www.charleysfund.org

--------------------------------------------------------------------------------
Source: AVI BioPharma, Inc.

Another one of the swine-flu outbreak.......

52wk Range: 0.45 - 1.68
Volume: 5,572,800
Avg Vol (3m): 234,449

Technicals
13-day EMA Cross Above 50-day MA
Percentage Gainer

Last Price Quote is:
33.34%above 13-day MA
34.36%above 50-day MA
RS Rating: 7 

Fundamentals
Key Data:
Market Cap (M): $76.22 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/11/2009
Last Analyst Rating: Buy

Amazing pipeline. Market cap is absurd for a company with this kind of technology and pipeline.
They're looking for a new CEO.
I expect huge things from AVII in the next few years.
NOTE: This is not an investment for the impatient.


52wk Range: 0.45 - 1.55
Volume: 448,679
Avg Vol (3m): 470,750

Technicals
Last Price Quote is:
9.15%above 13-day MA
26.30%above 50-day MA
RS Rating: 71 

Fundamentals
Key Data:
Market Cap (M): $93.35 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/10/2009
Last Analyst Rating: Buy

updated chart look...

Swine Flu Index Back on the Radar
the tickerspy.com Staff
On Wednesday June 3, 2009, 12:09 pm EDT

The W.H.O. is near declaring the H1/N1 virus a pandemic, but a hepatitis study drove the Swine Flu Index on Wednesday

Swine flu fears coverage has abated somewhat in the media, but the World Health Organization suggested this week that it may classify the threat as a worldwide pandemic. To date, 64 countries have been affected by the virus. Select swine flu stocks are flying today, although H1/N1 virus treatments cannot be given credit. Dynavax Technologies (NASDAQ: DVAX - News) reported positive Phase III data for its hepatitis B vaccine, sending the stock up by more than 36%. Overall, the sector is mixed, but some of its peers are following by as much as 15%.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 5.5%. It is now beating the S&P 500 by 33.5% over the last month.

AVI BioPharma (NASDAQ: AVII - News) and Hemispherx Biopharma (AMEX: HEB - News) are both following Dynavax higher by more than 14% today. Both are advancing to new 52-week highs.

Generex Biotechnology (NASDAQ: GNBT - News), Quidel (NASDAQ: QDEL - News), and Gilead Sciences (NASDAQ: GILD - News) are all trading higher by more than 4%.

Approximately half of the Swine Flu Index is in negative territory, led by BioCryst Pharmaceuticals (NASDAQ: BCRX - News), which is down -3%.

Other losers include Sanofi-Aventis (NYSE: SNY - News), GlaxoSmithKline (NYSE: GSK - News), and Novavax (NASDAQ: NVAX - News).

As of this writing the Swine Flu and Bird Flu Stocks Index is in the top-five performing tickerspy Indexes over the last month, gaining 40.2%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from nanotech to agriculture to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!

BreakOut !
The Golden Cross...
Any news hits this gets a good pop.......


52wk Range: 0.45 - 1.55
Volume: 2,129,819
Avg Vol (3m): 521,434

Technicals
Percentage Gainer

Last Price Quote is:
31.08%above 13-day MA
60.42%above 50-day MA
RS Rating: 93 

Fundamentals
Key Data:
Market Cap (M): $104.49 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/10/2009
Last Analyst Rating: Buy

updated chart look...

52wk Range: 0.45 - 1.69
Volume: 396,142
Avg Vol (3m): 613,649

Technicals
Last Price Quote is:
3.78%above 13-day MA
33.77%above 50-day MA
RS Rating: 91 

Fundamentals
Key Data:
Market Cap (M): $127.61 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/10/2009
Last Analyst Rating: Buy